The US company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer.

In October 2022, Normunity announced its launch and a Series A financing of $65 million which will be used to expand its pipeline.